A Phase I Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO) in Cardiac Surgery
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Sildenafil (Primary)
- Indications Acute kidney injury
- Focus Pharmacokinetics
- Acronyms REVAKI-1; REVAKI001
- 25 Oct 2016 Results published in the British Journal of Clinical Pharmacology
- 12 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.